Media & Resources

The Coalition for Epidemic Preparedness Innovations (CEPI) and IAVI announce partnership to develop a Lassa fever vaccine.

IAVI will receive a total of DKK 20 million (USD $3.18 million) from 2018-2021, administered by the Danish Ministry of Foreign Affairs.

Linda-Gail Bekker, Mark Dybul, and Christina Hull Paxson join IAVI Board in 1Q 2018.

IAS Past President David Cooper championed breakthrough AIDS treatment and advocated for a vaccine.

Novel HIV immunogens to be delivered via novel mRNA platform.

Reflections from colleagues Pat Fast, Mark Feinberg, Margaret McCluskey, and Bill Snow.

Read on for some of the discoveries IAVI and partners made in the latter half of 2017 and a look ahead at what’s to come.

What’s missing in HIV vaccine development? If you guessed political will or buy-in from pharmaceutical companies, you’d be wrong. According to Fran Priddy, IAVI’s Chief Medical Officer, it’s actually the virus itself, she explained at AtlanticLIVE’s Vaccines + Immunity event on November 9 in Philadelphia. The event convened top health officials and vaccine experts from…